Multinational pharmaceutical corporations are searching for means to broaden their capacity for drug development while decreasing costs. Pharmaceutical firms in India and China are increasingly forging partnerships with these corporations to gain revenue and to develop their own expertise. These relationships largely appear to be symbiotic. As a result of the movement of research to their countries, Indian and Chinese scientists are rapidly developing the ability to innovate and create their own intellectual property. Several firms in India and China are performing advanced R&D and are moving into the highest-value segments of the pharmaceutical global value chain. This research was funded in part by the Ewing Marion Kauffman Foundation.
View Article on SSRN
